Camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma failing first-line therapy: An open-label, single-arm, phase II study

被引：0
|
作者：
Ding, X. [1 ]
Zhang, W. [2 ]
You, R. [1 ]
Zou, X. [1 ]
Wang, Z. [3 ]
Ouyang, Y-F. [1 ]
Liu, Y-L. [1 ]
Peng, L. [1 ]
You-Ping, L. [1 ]
Duan, C-Y. [4 ]
Yang, Q. [1 ]
Lin, C. [1 ]
Yulong, X. [1 ]
Chen, S-Y. [1 ]
Gu, C-M. [1 ]
Huang, P. Y. [1 ]
Hua, Y. [1 ]
Chen, M. [1 ]
机构：
[1] Sun Yat Sen Univ, Dept Nasopharyngeal Carcinoma, Canc Ctr, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Nasopharyngeal Carcinoma, Canc Ctr, Guangzhou, Peoples R China
[3] Kunming Med Univ, Affiliated Hosp 1, Radiotherapy, Kunming, Yunnan, Peoples R China
[4] Southern Med Univ, Sch Publ Hlth, Biostat, Guangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.787
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
663P
引用
收藏
页码：S846 / S846
页数：1
相关论文
共 50 条
  • [41] Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
    Park, Joong-Won
    Finn, Richard S.
    Kim, Jun Suk
    Karwal, Mark
    Li, Ruby K.
    Ismail, Fuad
    Thomas, Melanie
    Harris, Rosemarie
    Baudelet, Christine
    Walters, Ian
    Raoul, Jean-Luc
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (07) : 1973 - 1983
  • [42] A prospective, single-arm, open-label study of camrelizumab, apatinib and nab-paclitaxel in patients with advanced cervical cancer
    Li, G.
    Zhao, Y.
    Jiang, Y.
    Yang, Q.
    Huang, A.
    Chen, Y.
    Han, D.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S753 - S754
  • [43] Open-label, single-arm phase II study of pemetrexed in the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma who have had prior platinum-based chemotherapy
    Zhang, Yang
    Zhao, Liping
    Huang, Peiyu
    Wu, Jingxun
    Wang, Fenghua
    Huang, Yan
    Zhang, Li
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (04) : 611 - 615
  • [44] Open-label, single-arm phase II study of pemetrexed in the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma who have had prior platinum-based chemotherapy
    Yang Zhang
    Liping Zhao
    Peiyu Huang
    Jingxun Wu
    Fenghua Wang
    Yan Huang
    Li Zhang
    [J]. Cancer Chemotherapy and Pharmacology, 2012, 70 : 611 - 615
  • [45] Neoadjuvant camrelizumab plus chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A single-arm, phase II trial
    Gao, Jin
    Qian, Liting
    Zhou, Lingran
    Sun, Bin
    He, Jian
    Wang, Ru
    Zhang, Yangyang
    Yang, Liping
    Zhou, Yan
    Yang, Jing
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
    Mao, Lili
    Fang, Meiyu
    Chen, Yu
    Wei, Xiaoting
    Cao, Jun
    Lin, Jing
    Zhang, Peng
    Chen, Ling
    Cao, Xiao
    Chen, Yujun
    Guo, Jun
    Si, Lu
    [J]. CLINICAL CANCER RESEARCH, 2022, 28 (21) : 4642 - 4648
  • [47] Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study
    Zhang, Qiyi
    Liu, Xingyu
    Wei, Shumei
    Zhang, Lufei
    Tian, Yang
    Gao, Zhenzhen
    Jin, Ming
    Yan, Sheng
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [48] A phase II, multicenter, open-label, single-arm trial of famitinib in patients with advanced recurrent and/or metastatic nasopharyngeal carcinoma (NPC) after two previous treatment regimens
    Huang, Yan
    Zhang, Li
    Pan, Jian-ji
    Hu, Guoqing
    Gang, Wu
    Xiong, Jian Ping
    Hu, Chaosu
    Lin, Lizhu
    Yu, Hao
    Jiang, Haoyuan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [49] Apatinib combined with camrelizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma: a prospective multicenter phase II study
    Mo, Yunyan
    Pan, Yufei
    Zhang, Bin
    Zhang, Jian
    Su, Yixin
    Liu, Zhengchun
    Luo, Meiqing
    Qin, Guanjie
    Kong, Xiangyun
    Zhang, Rongjun
    Pan, Yu
    Liang, Yi
    Wang, Defeng
    Wei, Yuejia
    Chen, Hengwei
    Jiang, Wei
    [J]. FRONTIERS IN IMMUNOLOGY, 2024, 14
  • [50] Camrelizumab plus apatinib combined with POF in patients with untreated advanced gastric cancer (UAGC): A singlecenter, open-label, single-arm, phase II trial (SYLT-017)
    Su, L.
    Zhao, S.
    Lin, P.
    Yin, Y.
    Lin, R.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1119 - S1120
12345